Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| GEPHA | Pharma | 14.2% | 49th pct | 110 |
| Georgia Pharmacy Group | Pharma | 13.5% | 46th pct | 110 |
| Aversi-Pharma | Pharma | 11.2% | 43rd pct | 110 |
| PSP Pharma | Pharma | 6.8% | 30th pct | 110 |
| Impexpharm | Pharma | 6.3% | 26th pct | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2024 | Aversi-Pharma | GEPHA | Georgia Pharmacy Group | PSP Pharma | Impexpharm |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 35.9% | 31.7% | 31.7% | 22.5% | 29.9% |
| EBITDA Margin | 11.2% | 14.2% | 13.5% | 6.8% | 6.3% |
| EBITDAR | 110,275 | 122,361 | 116,433 | 57,112 | 6,960 |
| EBITDAR Margin | 11.2% | 14.2% | 13.5% | 6.8% | 6.3% |
| EBIT Margin | 6.7% | 9.4% | 8.6% | 4.4% | 1.7% |
| Net Profit Margin | 6.4% | 6.0% | 3.1% | 3.4% | 2.6% |
| Operating Expense % of Sales | 25.2% | 18.0% | 18.7% | 15.7% | 23.5% |
| Returns | |||||
| Return on Assets (ROA) | 7.8% | 9.3% | 4.5% | 4.3% | 3.1% |
| Return on Equity (ROE) | 12.4% | 25.7% | 32.1% | 8.9% | 4.8% |
| ROIC [EBIT / Invested Capital] | 11.7% | ||||
| 22.1% |
| 18.9% |
| 8.9% |
| 2.5% |
| Leverage & debt balances | |||||
| Debt-to-Assets | 10.3% | 30.8% | 54.1% | 16.9% | 19.5% |
| Debt-to-Equity | 0.16x | 0.85x | 3.88x | 0.35x | 0.30x |
| Debt-to-EBITDA | 0.75x | 1.40x | 2.82x | 1.97x | 2.62x |
| Equity-to-Assets | 62.9% | 36.3% | 14.0% | 48.6% | 64.5% |
| Net Debt | 51,106 | 162,983 | 308,793 | 91,853 | 14,819 |
| Cash & Equivalents | 32,124 | 8,009 | 19,202 | 20,687 | 3,447 |
| Total Debt | 83,230 | 170,992 | 327,995 | 112,540 | 18,266 |
| Liquidity & working capital | |||||
| Current Ratio | 1.77x | 1.25x | 1.04x | 1.58x | 3.36x |
| Quick Ratio | 0.61x | 0.30x | 0.30x | 0.41x | 0.93x |
| Cash Ratio | 0.14x | 0.03x | 0.06x | 0.08x | 0.23x |
| Total Current Assets | 399,099 | 297,560 | 315,396 | 392,371 | 50,341 |
| Total Current Liabilities | 224,988 | 238,620 | 303,277 | 248,714 | 14,987 |
| Inventory | 261,916 | 225,239 | 225,344 | 291,297 | 36,452 |
| Trade Receivables | 113,508 | 45,553 | 45,553 | 76,883 | 4,885 |
| Trade Payables | 194,442 | 156,227 | 155,881 | 192,919 | 14,756 |
| Net Working Capital | 174,111 | 58,940 | 12,119 | 143,657 | 35,354 |
| Net Working Capital % of Revenue | 17.8% | 6.8% | 1.4% | 17.0% | 32.1% |
| Trade Working Capital | 180,982 | 114,565 | 115,016 | 175,261 | 26,582 |
| Trade Working Capital % of Revenue | 18.5% | 13.3% | 13.3% | 20.7% | 24.1% |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | N/A |
| Turnover & efficiency | |||||
| Inventory Turnover | 2.40x | 2.61x | 2.61x | 2.25x | 2.12x |
| Days Inventory Outstanding (DIO) | 152.2 | 139.7 | 139.8 | 162.3 | 172.2 |
| Receivables Turnover | 8.64x | 18.92x | 18.92x | 10.99x | 22.55x |
| Days Sales Outstanding (DSO) | 42.3 | 19.3 | 19.3 | 33.2 | 16.2 |
| Payables Turnover | 3.23x | 3.77x | 3.78x | 3.40x | 5.24x |
| Days Payable Outstanding (DPO) | 113.0 | 96.9 | 96.7 | 107.5 | 69.7 |
| Cash Conversion Cycle | 81.5 days | 62.1 days | 62.4 days | 88.0 days | 118.6 days |
| Asset Turnover | 1.21x | 1.55x | 1.42x | 1.27x | 1.18x |
| Cash flow & dividends | |||||
| Operating Cash Flow | 84,310 | 118,680 | 195,323 | 20,831 | 12,244 |
| Free Cash Flow (OCF − Capex proxy) | 11,960 | 89,858 | 139,632 | 19,867 | 8,715 |
| Cash Conversion (OCF / EBITDA) | 76.5% | 97.0% | 167.8% | 36.5% | 175.9% |
| Dividends Declared | 7,803 | 51,270 | 16,865 | 31,235 | 2,737 |
| Dividend Payout Ratio | 12.3% | 98.9% | 62.1% | 107.8% | 94.6% |